Ron Bentsur, CEO, Director at Keryx Biopharma, holds 3.24M shares in Nuvectis Pharma (Ticker: NVCT), holds 144.74K shares in Beyond Air (Ticker: XAIR), holds 0.00 shares in Stemline Therapeutics (Ticker: STML). Most recently, Ron Bentsur Bought ― shares of Nuvectis Pharma on Mar 19, 2024 for an estimated value of 51.45K.